Literature DB >> 14582918

Duration of length of stay in pneumonia: influence of clinical factors and hospital type.

R Menéndez1, M J Cremades, E Martínez-Moragón, J J Soler, S Reyes, M Perpiñá.   

Abstract

Length of stay (LOS) in hospital for community-acquired pneumonia depends on the characteristics of the patient and hospital. The present study sought to identify these variables within the first 24 h of hospitalisation. Patients hospitalised for pneumonia in four hospitals (one teaching and three general hospitals) had their data analysed by univariate and multivariate statististics. The variables entered were LOS, demographical characteristics, referral source, comorbidity, initial severity of illness, laboratory analyses, initial radiograph findings and antibiotic treatment regimens. The study sample included 425 patients. The overall mortality was 8.2% and the median LOS was 9 days. Using LOS as a dependent variable, three multivariate linear regression analyses were performed with: 1) the whole cohort; 2) the low-risk classes (categories I and II of Fine); and 3) the high-risk classes (categories III, IV and V of Fine). The mathematical model identified hypoxemia, low diastolic pressure, pleural effusion, multi-lobe involvement and hypoalbuminaemia as associated with longer stays in risk classes III-V, while in the low-risk patients (I-II) only hypoxemia and pleural effusion appeared in the equation. Following adjustment for these clinical variables, the LOS remained lower in some hospitals. Several independent clinical factors increased the pneumonia-associated length of stay with significant differences between hospitals. Hypoxemia and pleural effusions were the predictive variables of length of stay in low-risk patients and, additionally, diastolic blood pressure, multi-lobe involvement and hypoalbuminaemia were significant in the higher-risk classes III-V.

Entities:  

Mesh:

Year:  2003        PMID: 14582918     DOI: 10.1183/09031936.03.00026103

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

1.  Factors associated with length of stay in hospital for suspected community-acquired pneumonia.

Authors:  Jane Q Huang; Peter M Hooper; Thomas J Marrie
Journal:  Can Respir J       Date:  2006-09       Impact factor: 2.409

2.  Factors Affecting Cost of Patients with Severe Community-Acquired Pneumonia in Intensive Care Unit.

Authors:  Ayça Gümüş; Aykut Çilli; Özlem Çakın; Zuhal Karakurt; Begüm Ergan; Emine Aksoy; Melike Cengiz
Journal:  Turk Thorac J       Date:  2019-07-30

3.  Discordance of physician clinical judgment vs. pneumonia severity index (PSI) score to admit patients with low risk community-acquired pneumonia: a prospective multicenter study.

Authors:  Pedro J Marcos; Marcos I Restrepo; Francisco J González-Barcala; Nilam J Soni; Iria Vidal; Pilar Sanjuàn; Diego Llinares; Lucía Ferreira-Gonzalez; Carlos Rábade; Isabel Otero-González; Pedro Marcos; Héctor Verea-Hernando
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 4.  [Assessment, triage, and follow-up of a patient with: acute CAP COPD].

Authors:  K Faure
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

5.  Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives.

Authors:  Claudia Baehni; Sabine Meier; Pamela Spreiter; Ursula Schild; Katharina Regez; Rita Bossart; Robert Thomann; Claudine Falconnier; Mirjam Christ-Crain; Sabina De Geest; Beat Müller; Philipp Schuetz
Journal:  BMC Pulm Med       Date:  2010-03-11       Impact factor: 3.317

6.  Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study.

Authors:  Isabelle Suter-Widmer; Mirjam Christ-Crain; Werner Zimmerli; Werner Albrich; Beat Mueller; Philipp Schuetz
Journal:  BMC Pulm Med       Date:  2012-05-20       Impact factor: 3.317

7.  Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD.

Authors:  Ayfer Çolak; Celalettin Yılmaz; Burak Toprak; Serir Aktoğu
Journal:  J Med Biochem       Date:  2017-04-22       Impact factor: 3.402

8.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality.

Authors:  S Ewig; N Birkner; R Strauss; E Schaefer; J Pauletzki; H Bischoff; P Schraeder; T Welte; G Hoeffken
Journal:  Thorax       Date:  2009-05-18       Impact factor: 9.139

9.  Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England.

Authors:  Quentin J Leclerc; Naomi M Fuller; Ruth H Keogh; Karla Diaz-Ordaz; Richard Sekula; Malcolm G Semple; Katherine E Atkins; Simon R Procter; Gwenan M Knight
Journal:  BMC Health Serv Res       Date:  2021-06-09       Impact factor: 2.655

10.  Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial.

Authors:  Werner C Albrich; Kristina Rüegger; Frank Dusemund; Philipp Schuetz; Birsen Arici; Alexander Litke; Claudine A Blum; Rita Bossart; Katharina Regez; Ursula Schild; Merih Guglielmetti; Antoinette Conca; Petra Schäfer; Maria Schubert; Sabina de Geest; Barbara Reutlinger; Sarosh Irani; Ulrich Bürgi; Andreas Huber; Beat Müller
Journal:  Eur Respir J       Date:  2013-01-24       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.